DOV Pharmaceutical, Inc. (DOVP) announced Phase Ib results for DOV 21,947, its lead triple reuptake inhibitor for the treatment of depression and obesity.
From: www.nasdaq.com
DOVP: Positive Phase Ib Results for DOV 21,947
Posted by Ruslan Abuzant at 12:38 PM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment